Myelodysplastic syndrome: validation of flow cytometry multilineage score system

Abstract

Objective: To validate multilineage score system correlating results of flow cytometry, cytogenetics, cytomorphology and histology from samples of patients with suspected myelodysplastic syndrome or cytopenia of unknown origin. Methods: A retrospective study analyzing laboratory data of 49 patients with suspected myelodysplastic syndrome or cytopenia of unknown origin, carried out between May and September 2017. The inclusion criteria were availability of flow cytometry results, and at least one more method, such as morphology, histology or cytogenetics. Thirtyeight patients were classified as diagnosis of myelodysplastic syndromes, whereas 11 were classified as normal. Patients were evaluated based on score systems, Ogata score and flow cytometry multilineage score. Results: Comparing the scores obtained in the Ogata score and the multilineage score, it was observed that in four cases the Ogata score was zero or 1 point, while the multilineage score was higher than 3 points. In addition, in 12 cases with Ogata score of 2, the multilineage score was greater than 3. Conclusion: The flow cytometry multilineage score system demonstrated to be more effective in dysplasia analysis, by assessing the erythroid, monocytic, granulocytic and precursor cell lineages, apart from the parameters evaluated by the Ogata score.

Hallazgos morfológicos en síndromes mielodisplásicos

“…(15,17) El panel de EuroFlow para leucemia mieloide aguda (AML) y SMD apunta a la detección y clasificación, es decir, asignación de linaje y definición de perfil de maduración. (16,18,19) Más del 80 % de los pacientes con SMD tienen anemia en el momento del diagnóstico como resultado de la maduración eritroide alterada. (20) Los primeros marcadores utilizados para evaluar el fenotipo eritroide aberrante fueron la expresión de CD235a y CD71.…”